Drug General Information |
Drug ID |
D03VNX
|
Former ID |
DNAP001443
|
Drug Name |
Pro-urokinase
|
Synonyms |
Thrombolyse (TN)
|
Indication |
Thrombin deficiency [ICD9: 437.6, 444.9, 453, 671.5, 671.9; ICD10:I74, I80-I82, I82, O88, T79.0-T79.1]
|
Approved |
[1]
|
Target and Pathway |
Target(s) |
Urokinase-type plasminogen activator |
Target Info |
Modulator |
[2]
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
Complement and coagulation cascades
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
NetPath Pathway
|
IL2 Signaling Pathway
|
EGFR1 Signaling Pathway
|
PANTHER Pathway
|
Blood coagulation
|
Plasminogen activating cascade
|
CCKR signaling map ST
|
Pathway Interaction Database
|
Beta1 integrin cell surface interactions
|
E2F transcription factor network
|
Beta3 integrin cell surface interactions
|
Osteopontin-mediated events
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
amb2 Integrin signaling
|
ATF-2 transcription factor network
|
AP-1 transcription factor network
|
Beta2 integrin cell surface interactions
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
Beta5 beta6 beta7 and beta8 integrin cell surface interactions
|
FGF signaling pathway
|
Reactome
|
Dissolution of Fibrin Clot
|
WikiPathways
|
DNA Damage Response (only ATM dependent)
|
Senescence and Autophagy in Cancer
|
Complement and Coagulation Cascades
|
Endochondral Ossification
|
Wnt Signaling Pathway
|
Wnt Signaling Pathway and Pluripotency
|
Blood Clotting Cascade
|
Dissolution of Fibrin Clot
|
Osteopontin Signaling
|
References |
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
---|
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). |